Lexicon Pharmaceuticals Files 8-K on Financials
Ticker: LXRX · Form: 8-K · Filed: Nov 12, 2024
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: LXRP
TL;DR
Lexicon Pharma dropped an 8-K on Nov 12th - financials and ops update.
AI Summary
Lexicon Pharmaceuticals, Inc. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing is a standard regulatory disclosure for Lexicon Pharmaceuticals, Inc., providing investors and the public with updates on the company's financial status and operational results.
Risk Assessment
Risk Level: low — This filing is a routine regulatory disclosure and does not inherently present new risks.
Key Players & Entities
- LEXICON PHARMACEUTICALS, INC. (company) — Registrant
- November 12, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 2445 Technology Forest Blvd., 11th Floor (address) — Principal Executive Offices
- The Woodlands, Texas 77381 (address) — Principal Executive Offices City, State, Zip
- 281-863-3000 (phone_number) — Registrant's Phone Number
FAQ
What specific financial information is being reported in this 8-K?
The provided text indicates the filing is for 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not detail the specific financial figures within this excerpt.
When was this 8-K filing submitted?
The filing was submitted on November 12, 2024.
What is the principal executive office address for Lexicon Pharmaceuticals, Inc.?
The principal executive offices are located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the company's IRS Employer Identification Number?
The company's IRS Employer Identification Number is 76-0474169.
Filing Stats: 511 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-11-12 16:06:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
Filing Documents
- lxrx-20241112.htm (8-K) — 25KB
- pressreleaseearningsq311-1.htm (EX-99.1) — 99KB
- 0001062822-24-000057.txt ( ) — 257KB
- lxrx-20241112.xsd (EX-101.SCH) — 2KB
- lxrx-20241112_lab.xml (EX-101.LAB) — 21KB
- lxrx-20241112_pre.xml (EX-101.PRE) — 12KB
- lxrx-20241112_htm.xml (XML) — 3KB
02 Results of Operation and Financial Condition
Item 2.02 Results of Operation and Financial Condition On November 12, 2024, we issu ed a press release to report our financial results for the quarter ended September 30, 2024. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 — Press Release of Lexicon Pharmaceuticals, Inc. dated November 1 2 , 2024 EX-104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: November 12, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel